Abcam, ab5681, Anti-IGF1 Receptor (phospho Y1131+ Y1135+ Y1136) + INSR (phospho Y1158+ Y1162+ Y1163) antibody

Size: 50µL
Rabbit Polyclonal IGF1 Receptor phospho Y1131 + Y1135 + Y1136 antibody. Suitable for WB and reacts with Recombinant full length protein - Human samples. Cited in 11 publications. Immunogen corresponding to Synthetic Peptide within Human IGF1R phospho Y1131 + Y1135 + Y1136.
Key facts
Host species:Rabbit,
Clonality:Polyclonal,
Isotype:IgG,
Carrier free:No,
Reacts with:Human,
Applications:WBSee reactivity dataSee the reactivity data table below for information on validated species and application combinations.,
Immunogen:Synthetic Peptide within Human IGF1R phospho Y1131 + Y1135 + Y1136. The exact immunogen used to generate this antibody is proprietary information.P08069

Product details:
The antiserum was produced against a chemically synthesized phosphopeptide derived from the region of IR/IGF1R that contains tyrosines 1158, 1162 and 1163 of the human insulin receptor (IR) as numbered according to Ebina, et al. (1146, 1150 and 1151 according to Ullrich, et al.). The corresponding residues in the IGF1R are 1131, 1135 and 1136. The sequence is conserved in human, mouse and rat for both the IR and IGF1R.The two relevant papers are:Ebina, Y., et al. (1985) The human insulin receptor cDNA: the structural basis for hormone-activated transmembrane signalling. Cell 40(4):747-758.Ullrich, A., et al. (1985) Human insulin receptor and its relationship to the tyrosine kinase family of oncogenes. Nature 313(6005):756-761. There are a long and a short isoform of this protein. This is why we are listing 1158, 1162 and 1163 in the name (where these phospho sites in the long isoform) as well as 1146, 1150 and 1151 (for the short isoform).

Properties and Storage Information:
Form-Liquid, Purification technique-Affinity purification Immunogen, Purification notes-The antibody has been negatively preadsorbed using a non-phosphopeptide corresponding to the site of phosphorylation to remove antibody that is reactive with non-phosphorylated Insulin Receptor (IR). The final product is generated by affinity chromatography using an IR-derived peptide phosphorylated at tyrosines 1158, 1162 and 1163 (1131, 1135 and 1136 for IGF1R)., Storage buffer-pH: 7.3Preservative: 0.05% Sodium azideConstituents: PBS, 50% Glycerol (glycerin, glycerine), 0.1% BSA, Shipped at conditions-Blue Ice, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions--20°C, Aliquoting information-Upon delivery aliquot, Storage information-Avoid freeze / thaw cycle

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
The IGF1 Receptor often referred to as IGF-1R is a transmembrane receptor protein composed of alpha and beta subunits. Studies indicate that the IGF1R protein is involved in mediating the effects of insulin-like growth factor 1 (IGF-1) and plays an important role in cellular signaling. It has a molecular weight of approximately 180 kDa and is widely expressed in various tissues with high concentrations in the liver muscle and brain. Being a tyrosine kinase receptor IGF1R plays an essential role in growth and metabolism.
Biological function summary
IGF1R contributes to several cellular processes including cell proliferation differentiation and survival. This receptor forms a complex upon ligand binding and undergoes autophosphorylation to activate intracellular signaling cascades. IGF1R activation recruits and phosphorylates insulin receptor substrates enabling the downstream signaling pathways that promote cell growth and survival. Its function in cellular responses makes it a focal point in understanding cell biology.
Pathways
IGF1R holds a central position in the PI3K/AKT and MAPK signaling cascades. These pathways play significant roles in cellular growth proliferation and survival. IGF1R phosphorylates various downstream effectors such as IRS-1 and Shc linking it to the activation of AKT and ERK respectively. Therefore it shares pathways with related proteins like the insulin receptor highlighting its importance in mediating similar biological responses.
IGF1R has been implicated in cancers and diabetes. Overexpression of IGF1R has been observed in various malignancies including breast cancer where it relates to resistance in treatment and poor prognosis with cell lines like MCF-7 often being studied in this context. Additionally disruptions in IGF1R signaling link to insulin resistance an important feature of type 2 diabetes. These connections make IGF1R a potential therapeutic target with IGF1R inhibitors currently under exploration to address these health challenges.